Jennison Associates’s BioNTech BNTX Stock Holding History

Jennison Associates’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-49,900	Closed	-$5.45M	–	678
2021 Q1	$5.45M	Buy	+49,900	New	+$5.3M	﹤0.01%	466

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Jennison Associates's BNTX Position: Q2 2022 in Review

Jennison Associates sold out of BioNTech (BNTX) in Q2 2022, closing a stake of 185,818 shares — an estimated $31.7M sold.

Jennison Associates first reported a position in BNTX in Q1 2021 and held it in 5 quarters. The position peaked at $1.11B in Q3 2021. 293 funds tracked by Wall St. Rank hold BNTX as of Q2 2022.

Jennison Associates reported no remaining BioNTech position as of Q2 2022 after selling out during the quarter.
Jennison Associates sold 185,818 BioNTech shares in Q2 2022, an estimated $31.7M.
Jennison Associates first reported a position in BioNTech in Q1 2021 and held it in 5 quarters.
Jennison Associates's BioNTech position peaked at $1.11B in Q3 2021.
293 funds tracked by Wall St. Rank held BioNTech as of Q2 2022.

Based on Jennison Associates's 13F filing for Q2 2022, filed 2 Aug 2022.